# OnCo record checkmate-915 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/checkmate-915/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "checkmate-915", "NCT03068455" ;
  schema:name "CheckMate 915"@en ;
  schema:description "CheckMate 915 asked whether adding a low dose of ipilimumab to nivolumab after melanoma surgery would prevent more recurrences; it did not, and added toxicity, so single-agent PD-1 blockade remains the adjuvant standard."@en ;
  schema:url <https://onco.cc/trials/checkmate-915/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03068455> ;
  onco:status "negative" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/stage-iii-melanoma/>, <https://onco.cc/cancers/melanoma/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:people <https://onco.cc/people/jeffrey-weber/> .